Anil Vedula, MD
Ophthalmology · Plantation, FLNPI 1841527710
Payments from drug & device makers
Across 649 payments — averaging $128.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$49K
- Sight Sciences, Inc.$11K
- Alcon$6K
- Alcon Research LLC$5K
- AbbVie$4K
- NEW World Medical,inc.$2K
- plus $7K from 26 others
What the payments were for
- Consulting fees$32,76044%
- Speaking & faculty fees$14,00019%
- Travel & lodging$3,4505%
- Food & beverage$22,43030%
- Education$180%
- Gifts$1,5102%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 91 | $48,920 |
| Sight Sciences, Inc. | 45 | $10,856 |
| Alcon | 124 | $6,153 |
| Alcon Research LLC | 5 | $4,526 |
| AbbVie(2 entities) | 151 | $3,792 |
| NEW World Medical,inc. | 25 | $1,765 |
| Carl Zeiss Meditec, Inc. | 1 | $1,465 |
| Johnson & Johnson Surgical Vision, Inc. | 18 | $943 |
| Bausch & Lomb Americas Inc. | 29 | $737 |
| Glaukos Corporation | 19 | $711 |
| Sun Pharmaceutical Industries Inc. | 29 | $676 |
| Aerie Pharmaceuticals, Inc. | 16 | $488 |
| Novartis | 39 | $477 |
| Amgen(2 entities) | 5 | $330 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $275 |
| Dompe US, Inc. | 10 | $258 |
| Tarsus Pharmaceuticals, Inc. | 4 | $111 |
| Mallinckrodt Hospital Products Inc. | 3 | $99 |
| Topcon Healthcare, Inc. | 1 | $85 |
| Oyster Point Pharma, Inc. | 4 | $85 |
| Harrow Eye, LLC | 3 | $83 |
| Eyevance Pharmaceuticals LLC | 4 | $65 |
| Heru, Inc. | 2 | $49 |
| Rayner Intraocular Lenses Limited | 2 | $48 |
| Genentech USA, Inc. | 2 | $42 |
| Kala Pharmaceuticals, Inc. | 2 | $41 |
| Rxsight Inc | 2 | $34 |
| Thea Pharma Inc. | 2 | $31 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Akorn, Inc. | 1 | $22 |
| Shire North American Group Inc | 1 | $16 |
| Astellas Pharma US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prokera$21,534
- AmnioGraft$2,279
- CIRRUS photo$1,465
- Clareon$1,377
- AcrySof IQ VIVITY IOL$1,225
- LenSx$811
- OMNI(R) SURGICAL SYSTEM (US)$777
- Centurion$546
- Rhopressa$338
- Rocklatan$338
- DURYSTA$335
- SION SURGICAL INSTRUMENT$294
- Kahook Dual Blade$276
- Clearpath$276
- Ahmed Glaucoma Valve$276
- Streamline$276
- TEPEZZA$261
- ACTIVEFOCUS$252
- AcrySof$233
- Constellation$166
How this compares
$83,218 in reported general payments places this provider in the 90th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 16 | $801,766 |
| XiidraLifitegrast | 392 | $290,089 |
| RestasisCyclosporine | 331 | $242,741 |
| LumiganBimatoprost | 192 | $106,696 |
| VabysmoFaricimab-Svoa | 29 | $83,244 |
| EyleaAflibercept | 26 | $64,784 |
| CequaCyclosporine | 96 | $60,638 |
| EysuvisLoteprednol Etabonate | 114 | $55,329 |
| RhopressaNetarsudil Mesylate | 90 | $33,489 |
| Prednisolone Acetate | 666 | $32,339 |
| AlrexLoteprednol Etabonate | 48 | $26,496 |
| MieboPerfluorohexyloctane/Pf | 23 | $24,476 |
| RocklatanNetarsudil Mesylat/Latanoprost | 58 | $23,033 |
| IlevroNepafenac | 62 | $22,835 |
| CombiganBrimonidine Tartrate/Timolol | 45 | $21,142 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $258 | $801,76616 claims |
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $3,792 | $381,012609 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $737 | $320,770430 claims |
| Genentech USA, Inc.Vabysmo | $42 | $83,24429 claims |
| Regeneron Healthcare Solutions, Inc.Eylea | $22 | $64,78426 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $676 | $60,63896 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $488 | $56,521148 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $41 | $55,329114 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCAlrex, Loteprednol Etabonate, Prolensa | $275 | $53,731171 claims |
| NovartisIlevro | $477 | $22,83562 claims |
| AlconSimbrinza | $6,153 | $8,00332 claims |
| Eyevance Pharmaceuticals LLCTobradex St, Flarex | $65 | $4,56324 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Plantation
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
- Carl DanzigPompano Beach$5.3M
- Bruce SegalDelray Beach$4.7M
- Cathleen McCabeBradenton$4.6M
- Ivan SunerTampa$3.7M
- Sunir JoshiFt Lauderdale$3.7M
- Harold BrooksTallahassee$3.5M
- Matthew CunninghamOrlando$2.9M
- Benjamin ThomasJacksonville$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.